Swiss Rockets is dedicated to developing groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders – advancing more effective, equitable, and accessible healthcare for patients worldwide.
Products, services, technology
Rocketvax pioneers the development of innovative vaccines to combat infectious diseases.
Torqur advances next-generation dual PI3K/mTOR inhibitors.
Torpedo develops next-generation radioligand therapies using Terbium-161.
Cooperation possibilities
Swiss Rockets develops and accelerates portfolio companies in oncology, radioligand therapy, neurology, infectious diseases, and gene sequencing. We provide scientific expertise, operational infrastructure, and global networks to drive research, development, commercialization, and innovation.
- https://swissrockets.com
- +41 61 561 54 10
- Send an email
- Vladimir Cmiljanovic
Some insights
Swiss Rockets advances innovative therapies and technologies that address urgent medical needs. By building and supporting breakthrough biotech companies, we aim to improve patient outcomes and help shape a healthier future.
We are proud to help transform scientific innovation into real solutions that improve and save lives. By advancing breakthrough therapies, we bring hope to patients and families affected by serious diseases.
We admire organizations and leaders that combine scientific excellence with genuine patient impact, those who drive innovation responsibly, accelerate access to advanced treatments, and set high standards for ethical collaboration and global health improvement.
We bring together scientific excellence, proven drug-development expertise, and a collaborative mindset. Going forward, we aim to expand our commercial, regulatory, and clinical operations capabilities to accelerate global scale and market readiness.
Support through broader investment access, stronger connections with strategic partners, and more integrated networks between industry, academia, and hospitals would help accelerate development and scale our technologies globally.
